Shubin Qiao, Lianglong Chen, et al
The Resolute™ zotarolimus-eluting stent (ZES) (Medtronic, Minneapolis, MN, USA) has been associated with excellent and sustained safety and efficacy in real-world populations undergoing percutaneous coronary intervention (PCI). In the RESOLUTE All-Comers trial of Resolute ZES (N=1,140) vs. XIENCE V™ everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, CA, USA; N=1,152), conducted in an all-comers population across Europe, target vessel failure (a composite of cardiac death, myocardial infarction [MI] not clearly attributable to a non-target vessel, and clinically indicated target vessel revascularisation) at five years was 20% with Resolute ZES (and no different from XIENCE V EES, 19%, p=0.60)1. Moreover, given the excellent safety and efficacy of current-generation drug-eluting stents, the stents are used to treat an increasingly complex patient population, including those with small vessels, bifurcation lesions, and chronic total occlusions.